The effect of intracavernous injection of @entity972 channel openers in monkeys and XXXX .

@entity1 @entity323 @entity31802 @entity235 @entity2507 @entity972 @entity121 @entity1706
Cavernous smooth @entity121 is effected through a complex biochemical pathway; therefore, a defect in any step of this pathway may result in @entity323 . Administration of pharmacologic agents which cause relaxation of the cavernous smooth muscle through a different mechanism may serve as an effective therapeutic alternative for @entity323 @entity1 . To test this hypothesis two @entity972 channel openers, @entity1706 and @entity31802 , were used to initiate and maintain cavernous smooth @entity121 . The drugs were given as intracavernous injections in two animal models. In 10 @entity235 @entity1706 and @entity31802 produced full erection. With @entity1706 (10(-2) M), the mean intracavernous pressure increased from a baseline pressure of 32.6 +/- 3.43 cm @entity2507 to a peak intracavernous pressure of 131.8 +/- 12.01 cm @entity2507 , and remained elevated for a period of 17.8 +/- 9.4 min. With @entity31802 (10(-2) M) intracavernous pressure rose from a baseline pressure of 32 +/- 2.55 cm @entity2507 to a peak intracavernous pressure of 140 +/- 3.39 cm @entity2507 , for a period of 19.4 +/- 0.89 min. Additionally, in 5 primates injected with @entity31802 (10(-2) M) intracavernous pressure rose from 24 +/- 3.81 to 131.2 +/- 7.56 cm @entity2507 , for 27.0 +/- 4.79 min. It is concluded that both @entity1706 and @entity31802 can initiate and maintain erection in @entity235 and that @entity31802 produces a similar erectile response in monkeys. Further study of the local and systemic effects of chronic injection is needed to determine whether this class of pharmacologic agents can provide therapy for @entity323 @entity1 .
